Stock Watch: Some Turbulence As Novo And Lilly Report Results

Investors Should Value Birds In The Hand Above Fledglings In The Bush

Novo disappointed on high expectations with its second-quarter announcement resulting in stock price weakness. But after Lilly reported without disappointment, something unexpected happened.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business